AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
AstraZeneca PLC LSE:AZN
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.